1. Home
  2. GGZ vs MGNX Comparison

GGZ vs MGNX Comparison

Compare GGZ & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gabelli Global Small and Mid Cap Value Trust (The) of Beneficial Interest

GGZ

Gabelli Global Small and Mid Cap Value Trust (The) of Beneficial Interest

HOLD

Current Price

$15.33

Market Cap

112.4M

Sector

Finance

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$1.73

Market Cap

112.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GGZ
MGNX
Founded
2013
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
112.4M
112.6M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
GGZ
MGNX
Price
$15.33
$1.73
Analyst Decision
Hold
Analyst Count
0
5
Target Price
N/A
$3.20
AVG Volume (30 Days)
12.8K
919.7K
Earning Date
01-01-0001
11-12-2025
Dividend Yield
5.39%
N/A
EPS Growth
N/A
N/A
EPS
1.75
N/A
Revenue
N/A
$127,626,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.79
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.43
$0.99
52 Week High
$12.50
$3.37

Technical Indicators

Market Signals
Indicator
GGZ
MGNX
Relative Strength Index (RSI) 77.84 63.44
Support Level $15.33 $1.68
Resistance Level $15.70 $1.82
Average True Range (ATR) 0.19 0.10
MACD 0.04 -0.00
Stochastic Oscillator 100.00 78.13

Price Performance

Historical Comparison
GGZ
MGNX

About GGZ Gabelli Global Small and Mid Cap Value Trust (The) of Beneficial Interest

The Gabelli Global Small and Mid Cap Value Trust is a diversified closed-ended management investment company whose investment objective is long-term capital growth. It invests in equity securities such as common stock and preferred stock of companies.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: